1170 related articles for article (PubMed ID: 25398450)
1. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
[TBL] [Abstract][Full Text] [Related]
3. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Xia C; Ribeiro M; Scott S; Lonial S
Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
7. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Krejcik J; Frerichs KA; Nijhof IS; van Kessel B; van Velzen JF; Bloem AC; Broekmans MEC; Zweegman S; van Meerloo J; Musters RJP; Poddighe PJ; Groen RWJ; Chiu C; Plesner T; Lokhorst HM; Sasser AK; Mutis T; van de Donk NWCJ
Clin Cancer Res; 2017 Dec; 23(24):7498-7511. PubMed ID: 29025767
[No Abstract] [Full Text] [Related]
8. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
[TBL] [Abstract][Full Text] [Related]
9. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Asvadi P; Cuddihy A; Dunn RD; Jiang V; Wong MX; Jones DR; Khong T; Spencer A
Br J Haematol; 2015 May; 169(3):333-43. PubMed ID: 25653020
[TBL] [Abstract][Full Text] [Related]
10. CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
Laubach JP; Richardson PG
Clin Cancer Res; 2015 Jun; 21(12):2660-2. PubMed ID: 25878332
[TBL] [Abstract][Full Text] [Related]
11. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
12. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Blair HA
Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
[TBL] [Abstract][Full Text] [Related]
15. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
[TBL] [Abstract][Full Text] [Related]
16. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
Yu T; Chaganty B; Lin L; Xing L; Ramakrishnan B; Wen K; Hsieh PA; Wollacott A; Viswanathan K; Adari H; Cho SF; Li Y; Chen H; Yang W; Xu Y; An G; Qiu L; Munshi N; Babcock G; Shriver Z; Myette JR; Anderson KC; Tai YT
Blood Cancer J; 2020 Nov; 10(11):110. PubMed ID: 33149123
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab granted breakthrough drug status.
Laubach JP; Tai YT; Richardson PG; Anderson KC
Expert Opin Investig Drugs; 2014 Apr; 23(4):445-52. PubMed ID: 24555809
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab plus bortezomib and dexamethasone
Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka AK; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott EC; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Soong D; Casneuf T; Chiu C; Amin H; Qi M; Thiyagarajah P; Sasser AK; Schecter JM; Mateos MV
Haematologica; 2018 Dec; 103(12):2079-2087. PubMed ID: 30237264
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]